Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
7 studies found for:    "membranoproliferative glomerulonephritis type II" OR "Glomerulonephritis, Membranoproliferative"
Show Display Options
Rank Status Study
1 Terminated Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
Conditions: Dense Deposit Disease;   Membranoproliferative Glomerulonephritis Type II;   C3 Glomerulonephritis
Intervention: Drug: CDX-1135
2 Active, not recruiting Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Conditions: Dense Deposit Disease;   Membranoproliferative Glomerulonephritis
Intervention: Drug: Eculizumab
3 Completed Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis
Condition: Glomerulonephritis, Membranoproliferative
Intervention: Drug: Rituximab
4 Terminated Sulodexide Treatment in Patients With Dense Deposit Disease
Condition: Dense Deposit Disease
Intervention: Drug: Sulodexide
5 Recruiting Eculizumab in Primary MPGN
Condition: Membranoproliferative Glomerulonephritis
Intervention: Drug: Eculizumab
6 Completed BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis
Conditions: Glomerulonephritis, Membranoproliferative;   Lupus Nephritis
Intervention: Drug: BG9588
7 Recruiting TP10 Use in Patients With C3 Glomerulopathy (C3G)
Condition: Dense Deposit Disease
Intervention: Drug: TP10

Indicates status has not been verified in more than two years